Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.8250
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
0.8356
+0.0106 (1.28%)
After-hours: Mar 28, 2025, 7:46 PM EDT
Kronos Bio Employees
Kronos Bio had 10 employees as of December 31, 2024. The number of employees decreased by 53 or -84.13% compared to the previous year.
Employees
10
Change (1Y)
-53
Growth (1Y)
-84.13%
Revenue / Employee
$984,800
Profits / Employee
-$8,607,900
Market Cap
50.30M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10 | -53 | -84.13% |
Dec 31, 2023 | 63 | -34 | -35.05% |
Dec 31, 2022 | 97 | 1 | 1.04% |
Dec 31, 2021 | 96 | 33 | 52.38% |
Dec 31, 2020 | 63 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KRON News
- 12 days ago - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 months ago - Kronos Bio Announces CEO Transition and Reduction in Force - GlobeNewsWire
- 4 months ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 5 months ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 months ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 months ago - Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - GlobeNewsWire
- 6 months ago - Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - GlobeNewsWire
- 6 months ago - Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - GlobeNewsWire